Alvaro Moreno Aspitia, MD, FAAP, FACP

Associate Professor

  • 1309 Citations
  • 19 h-Index
20002019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 7 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Anthracyclines Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Triple Negative Breast Neoplasms Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2000 2019

  • 1309 Citations
  • 19 h-Index
  • 57 Article

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

Lambertini, M., Campbell, C., Bines, J., Korde, L. A., Izquierdo, M., Fumagalli, D., Del Mastro, L., Ignatiadis, M., Pritchard, K., Wolff, A. C., Jackisch, C., Lang, I., Untch, M., Smith, I., Boyle, F., Xu, B., Barrios, C. H., Baselga, J., Moreno Aspitia, A., Piccart, M. & 2 othersGelber, R. D. & de Azambuja, E., Jan 1 2019, In : Journal of the National Cancer Institute. 111, 1, p. 86-94 9 p.

Research output: Contribution to journalArticle

Amenorrhea
Breast Neoplasms
Survival
Hormones
Therapeutics

AlternativeOutpatientChemotherapy scheduling method to improve patient service quality and nurse satisfaction

Huang, Y. L., Bryce, A. H., Culbertson, T., Connor, S. L., Looker, S. A., Altman, K. M., Collins, J. G., Stellner, W., Mc Williams, R. R., Moreno Aspitia, A., Ailawadhi, S. & Mesa, R. A., Feb 1 2018, In : Journal of Oncology Practice. 14, 2, p. e82-e91

Research output: Contribution to journalArticle

Nurses
Workload
Safety
Drug Therapy
Nursing Staff
4 Citations

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine

Yu, J., Qin, B., Moyer, A. M., Nowsheen, S., Liu, T., Qin, S., Zhuang, Y., Liu, D., Lu, S. W., Kalari, K. R., Visscher, D. W., Copland, J. A. III., McLaughlin, S. A., Moreno Aspitia, A., Northfelt, D. W., Gray, R. J., Lou, Z., Suman, V. J., Weinshilboum, R. M., Boughey, J. C. & 2 othersGoetz, M. P. & Wang, L. M., Jun 1 2018, In : Journal of Clinical Investigation. 128, 6, p. 2376-2388 13 p.

Research output: Contribution to journalArticle

decitabine
Triple Negative Breast Neoplasms
Methyltransferases
DNA
Biomarkers

High p95HER2/HER2 ratio associated with poor outcome in trastuzumab-treated HER2-positive metastatic breast cancer ncctg N0337 and NCCTG 98-32-52 (Alliance)

Chumsri, S., Sperinde, J., Liu, H., Gligorov, J., Spano, J. P., Antoine, M., Moreno Aspitia, A., Tan, W., Winslow, J., Petropoulos, C. J., Chenna, A., Bates, M., Weidler, J. M., Huang, W., Dueck, A. & Perez, E. A., Jul 1 2018, In : Clinical Cancer Research. 24, 13, p. 3053-3058 6 p.

Research output: Contribution to journalArticle

Disease-Free Survival
Breast Neoplasms
Research Design
Therapeutics
Biomarkers
1 Citations

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials

Lambertini, M., Martel, S., Campbell, C., Guillaume, S., Hilbers, F. S., Schuehly, U., Korde, L., Azim, H. A., Di Cosimo, S., Tenglin, R. C., Huober, J., Baselga, J., Moreno Aspitia, A., Piccart-Gebhart, M., Gelber, R. D., de Azambuja, E. & Ignatiadis, M., Jan 1 2018, (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

Breast Neoplasms
Pregnancy
Therapeutics
Down Syndrome
Disease-Free Survival